Regeneron Pharmaceuticals Inc. (REGN) Falls 3.98% for February 05

Equities Staff |

One of the S&P 500’s big losers for Friday February 05 was Regeneron Pharmaceuticals Inc. (REGN). The company’s stock fell 3.98% to $396.16 on volume of 1.07 million shares.

The stock opened the day at 416.10 and traded between a low of $393.50 and a high of $420.53. The stock finished the day down $16.43 per share. Regeneron Pharmaceuticals Inc. has an average daily volume of 887,525 and a total float of 104.07 million shares. The 50-day SMA for Regeneron Pharmaceuticals Inc. is $508.25 and its 200-day SMA is $520.64. The high for the stock over the last 52 weeks is $605.93 and the low is $392.35.

Regeneron Pharmaceuticals Inc is a fully integrated biopharmaceutical company. It discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions.

Regeneron Pharmaceuticals Inc. is centered in Tarrytown, NY, and has 2,925 employees. Today’s trading day leaves the company with a market cap of $41.23 billion. The company has a P/S ratio of n/a, P/B ratio of 12.51, and a 87.9.

For a complete fundamental analysis analysis of Regeneron Pharmaceuticals Inc., check out Equities.com’s Stock Valuation Analysis report for REGN. To see the latest independent stock recommendations from Equities.com’s analysts, visit our Research section.

The S&P 500 represents the industry standard for large-cap indices. While the Dow Jones Industrial Average (DJIA) may be the most visible stock market index in the country, the S&P 500 has long been relied on by industry insiders and fund managers as the more reliable gauge of portfolio performance.

While the DJIA is price-weighted and only includes 30 stocks, the S&P 500 uses a weighting system that factors in market cap and the size of a company’s free float while including some 500 stocks for a more comprehensive look at the broader markets’ performance. Its performance is far more representative of the large- and mega-cap stocks for any period of time.

For more news on the financial markets, go to Equities.com. Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Comments

Emerging Growth

Relevium Technologies Inc.

Relevium Technologies Inc is engaged in the acquisition of products, technologies and businesses relating to musculoskeletal function, specifically Pain Relief, Injury Recovery and Active Performance.

Private Markets

D-Wave

D-Wave Systems is the first quantum computing company. Its mission is to integrate new discoveries in physics, engineering, manufacturing, and computer science into breakthrough approaches to computation to help solve…

Initial State

Initial State is an Internet of Things (IoT) data analytics & data management platform company. We turn sensor and event data into information that matters by making it easy to…